

VIA FACSIMILE March 5, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lafleur et al.

Application Serial No.: 09/487,792

Art Unit: 1647

Filed: January 20, 2000

Examiner: Seharaseyon, J.

For: Keratinocyte Derived Interferon

Attorney Docket No.: PF482P1

SUPPLEMENTAL AMENDMENT TO PAPER NO. 15 UNDER 37 C.F.R. § 1.111Commissioner for Patents
Washington, D.C. 20231

Sir:

Further to Applicants' response filed on January 23, 2002 to the Office Action dated October 23, 2001, (Paper No. 15), please consider the following supplemental amendments and remarks. Applicants submit herewith the following: (a) a Fee Transmittal Sheet; and (b) Version To Show Changes Made. Please amend the application as follows:

In the Claims:

Please cancel claims 56, 85, 86, 94-135 without prejudice or disclaimer.

Please enter the following amended claims:

C¹ 10 ~~80~~. (Once Amended) A composition comprising the protein of claim ~~41~~ and a acceptable carrier.

C² 13 ~~83~~. (Once Amended) An isolated protein comprising a polypeptide having an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203500; and

(b) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203500 excluding the N-terminal methionine residue.

C³ 20 ~~61~~. (Once Amended) A composition comprising the protein of claim ~~53~~ and a acceptable carrier.